Tumor Associated Macrophages News and Research

RSS

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Integrated nanomaterials offer new strategies for cancer immunotherapy

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not achieve lasting benefit.

9 Aug 2026

D-serine promotes gastric cancer growth by suppressing tumor immunity

Researchers from Keio University have found that D-serine increases the growth of gastric cancer by creating an immunosuppressive and anti-inflammatory tumor microenvironment.

6 Aug 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Adaptor proteins regulate macrophage behavior to control cancer growth

A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression."

7 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Engineered silica nanoparticles destroy prostate tumors in preclinical study

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell College of Engineering.

15 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

New review highlights how glutamine metabolism shapes the complex tumor microenvironment

A new review article highlights the expanding importance of glutamine metabolism in shaping the tumor microenvironment, offering fresh perspectives on how metabolic interactions influence cancer progression and therapeutic response

25 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Nerve fibers within melanomas found to slow tumor growth

Nerve fibers within melanomas can slow the growth of these tumors, according to a study led by Weill Cornell Medicine investigators.

29 Apr 2026

New immune mapping tool reveals how lung cancer reshapes immune cells

Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors.

27 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

Protein MIIP suppresses colorectal cancer by regulating immune cell signaling

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and limited responses to immunotherapy in most patients.

16 Mar 2026

New therapeutic approach converts immune cells inside tumors into anticancer cell therapies

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor.

2 Jan 2026

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies.

5 Dec 2025

New combination treatment overcomes resistance in ER positive breast cancer

In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.

6 Nov 2025

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025